UA116004C2 - Фармацевтична композиція з покращеною біодоступністю - Google Patents

Фармацевтична композиція з покращеною біодоступністю

Info

Publication number
UA116004C2
UA116004C2 UAA201507997A UAA201507997A UA116004C2 UA 116004 C2 UA116004 C2 UA 116004C2 UA A201507997 A UAA201507997 A UA A201507997A UA A201507997 A UAA201507997 A UA A201507997A UA 116004 C2 UA116004 C2 UA 116004C2
Authority
UA
Ukraine
Prior art keywords
improved bioavailability
pharmaceutical composition
chloro
compounds
melhylpropyl
Prior art date
Application number
UAA201507997A
Other languages
English (en)
Inventor
Стів Ломуссіо
Хуа Ма
Майкл Аллен Метчетт
Харпреет К. Сендху
Навніт Харговіндас Шах
Ю-Е Чжан
Original Assignee
Ф. Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50023547&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA116004(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ф. Хоффманн-Ля Рош Аг filed Critical Ф. Хоффманн-Ля Рош Аг
Publication of UA116004C2 publication Critical patent/UA116004C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Винахід стосується твердих дисперсій слаборозчинних у воді сполук, зокрема 4-{[(2R,3S,4R,5S)-4-(4-хлор-2-фторфеніл)-3-(3-хлор-2-фторфеніл)-4-ціано-5-(2,2-диметилпропіл)-піролідин-2-карбоніл]-аміно}-3-метоксибензойної кислоти, що утворюється сумісним осадженням з розчинником або сушінням розпиленням, що дає в результаті покращені біодоступність, безпеку і переносимість зазначених сполук.
UAA201507997A 2013-01-22 2014-01-20 Фармацевтична композиція з покращеною біодоступністю UA116004C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361755074P 2013-01-22 2013-01-22
PCT/EP2014/050974 WO2014114575A1 (en) 2013-01-22 2014-01-20 Pharmaceutical composition with improved bioavailability

Publications (1)

Publication Number Publication Date
UA116004C2 true UA116004C2 (uk) 2018-01-25

Family

ID=50023547

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201507997A UA116004C2 (uk) 2013-01-22 2014-01-20 Фармацевтична композиція з покращеною біодоступністю

Country Status (24)

Country Link
US (2) US9427427B2 (uk)
EP (1) EP2948141A1 (uk)
JP (1) JP6192244B2 (uk)
KR (1) KR101737250B1 (uk)
CN (3) CN104936589A (uk)
AR (1) AR094548A1 (uk)
AU (1) AU2014210103B2 (uk)
BR (1) BR112015015758B1 (uk)
CA (1) CA2892025C (uk)
CL (1) CL2015001649A1 (uk)
CR (1) CR20150287A (uk)
EA (1) EA028009B1 (uk)
HK (1) HK1211217A1 (uk)
IL (1) IL239657B (uk)
MA (1) MA38289A1 (uk)
MX (1) MX2015008911A (uk)
MY (1) MY192032A (uk)
NZ (1) NZ708272A (uk)
PE (1) PE20151335A1 (uk)
PH (1) PH12015501620A1 (uk)
SG (1) SG11201504499VA (uk)
UA (1) UA116004C2 (uk)
WO (1) WO2014114575A1 (uk)
ZA (1) ZA201504187B (uk)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160138307A (ko) * 2014-04-15 2016-12-02 에프. 호프만-라 로슈 아게 약학적으로 활성인 화합물의 고체 형태
PT107846B (pt) * 2014-08-01 2019-03-22 Hovione Farm S A Produção de nano- partículas de dispersões sólidas amorfas por co-precipitação controlada
WO2016090101A1 (en) * 2014-12-05 2016-06-09 Aragon Pharmaceuticals, Inc. Anticancer compositions
EP3226843B1 (en) 2014-12-05 2021-05-26 Aragon Pharmaceuticals, Inc. Anticancer compositions
CA2987867C (en) * 2015-06-09 2023-06-27 Capsugel Belgium Nv Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
GB201609222D0 (en) 2016-05-25 2016-07-06 F2G Ltd Pharmaceutical formulation
BR112018072382A2 (pt) * 2017-04-21 2019-02-12 Bio-Synectics Inc. método para preparar nanopartícula de ingrediente ativo
JP7190452B2 (ja) * 2017-07-04 2022-12-15 ジエンス ヘンルイ メデイシンカンパニー リミテッド 医薬組成物及びその製造方法
ES2967689T3 (es) 2018-04-06 2024-05-03 Capsugel Belgium Nv Proceso de secado por aspersión para partículas de baja relación de aspecto que comprenden poli[(metacrilato de metilo)-co-(ácido metacrílico)]
WO2019213106A1 (en) 2018-04-30 2019-11-07 Teva Pharmaceuticals International Gmbh Solid state forms of idasanutlin
TWI849043B (zh) * 2019-01-25 2024-07-21 英屬開曼群島商百濟神州有限公司 B-raf激酶二聚體抑制劑之穩定固體分散體、製備方法及其用途
US11819503B2 (en) 2019-04-23 2023-11-21 F2G Ltd Method of treating coccidioides infection
TW202100527A (zh) * 2019-05-31 2021-01-01 大陸商江蘇恆瑞醫藥股份有限公司 一種固體分散體及其製備方法
US20230147869A1 (en) * 2019-09-23 2023-05-11 Bionomics Limited Therapeutic formulations and uses thereof
IL293268A (en) * 2019-12-02 2022-07-01 Astrazeneca Ab Solid pharmaceutical formulations of 6-(2-chloro-6-methylpyridin-4-yl)-5-(-4-fluorophenyl)-1,2,4-triazine-3-amine
ES2963626T3 (es) * 2019-12-20 2024-04-01 Intervet Int Bv Una composición farmacéutica de un compuesto de pirazol dispersado en una matriz polimérica
TW202211911A (zh) * 2020-06-05 2022-04-01 美商應用材料股份有限公司 經塗佈的藥物組成物及製備彼之方法
CN112022812B (zh) * 2020-11-03 2021-01-29 上海亚盛医药科技有限公司 一种包含杂环类化合物的组合物、其制备方法和应用
CN116887866A (zh) 2020-12-03 2023-10-13 巴特尔纪念研究院 聚合物纳米颗粒和dna纳米结构组合物及用于非病毒递送的方法
WO2022216977A1 (en) 2021-04-07 2022-10-13 Batelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
EP4119128A1 (en) * 2021-07-13 2023-01-18 Dr. Falk Pharma Gmbh Pharmaceutical composition for the oral administration of poorly soluble drugs comprising an amorphous solid dispersion
WO2024025609A1 (en) * 2022-07-26 2024-02-01 Wellstat Therapeutics Corporation Uridine triacetate amorphous formulation and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
GB9511220D0 (en) * 1995-06-02 1995-07-26 Glaxo Group Ltd Solid dispersions
CN1165291C (zh) 1996-05-20 2004-09-08 詹森药业有限公司 具有改进的生物利用度的抗真菌组合物
SE9700655L (sv) 1997-02-25 1998-05-11 Neste Oy Förfarande för framställning av ftalsyraanhydrid
US6350786B1 (en) 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
PL348193A1 (en) 1998-12-11 2002-05-06 Pharmasolutions Self-emulsifying compositions for drugs poorly soluble in water
ES2306646T3 (es) 1999-02-09 2008-11-16 Pfizer Products Inc. Composiciones de farmacos basicos con biodisponibilidad incrementada.
US6057289A (en) 1999-04-30 2000-05-02 Pharmasolutions, Inc. Pharmaceutical composition comprising cyclosporin in association with a carrier in a self-emulsifying drug delivery system
CN1224423C (zh) 2000-07-17 2005-10-26 山之内制药株式会社 改善口服吸收的医药组合物
ATE381922T1 (de) 2000-10-31 2008-01-15 Boehringer Ingelheim Pharma Perorale, selbst-emulgierende darreichungsformen von pyranon-proteaseinhibitoren
US20050255164A1 (en) 2002-08-15 2005-11-17 Yunging Liu Solid nano pharmaceutical formulation and preparation method thereof
US7438261B2 (en) 2004-09-09 2008-10-21 David R. Porter Stratospheric balloon utilizing electrostatic inflation of walls
KR20140107691A (ko) 2006-03-20 2014-09-04 버텍스 파마슈티칼스 인코포레이티드 의약 조성물
US8354444B2 (en) * 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
CN105237530A (zh) 2009-04-03 2016-01-13 豪夫迈罗氏公司 丙烷-1-磺酸{3-[5-(4-氯-苯基)-1H-吡咯并[2,3-b]吡啶-3-羰基]-2,4-二氟-苯基}-酰胺组合物及其用途
CN102871950B (zh) 2011-07-15 2016-04-20 上海睿智化学研究有限公司 一种熊果酸固体分散体及其制备方法
US20130245089A1 (en) * 2012-03-19 2013-09-19 Hoffmann-La Roche Inc. Method for administration
US20140128431A1 (en) * 2012-04-03 2014-05-08 Hoffmann-Laroche Inc. Pharmaceutical composition with improved bioavailability, safety and tolerability

Also Published As

Publication number Publication date
IL239657B (en) 2019-05-30
AU2014210103A1 (en) 2015-06-11
EP2948141A1 (en) 2015-12-02
KR20150097792A (ko) 2015-08-26
HK1211217A1 (en) 2016-05-20
CN112353762A (zh) 2021-02-12
EA028009B1 (ru) 2017-09-29
WO2014114575A1 (en) 2014-07-31
KR101737250B1 (ko) 2017-05-17
MA38289A1 (fr) 2017-01-31
MX2015008911A (es) 2015-10-22
JP6192244B2 (ja) 2017-09-06
ZA201504187B (en) 2018-11-28
US10034854B2 (en) 2018-07-31
PH12015501620B1 (en) 2015-09-28
CA2892025A1 (en) 2014-07-31
CR20150287A (es) 2015-09-01
PE20151335A1 (es) 2015-09-18
BR112015015758A2 (pt) 2018-06-19
CA2892025C (en) 2022-02-15
NZ708272A (en) 2020-07-31
US20140206742A1 (en) 2014-07-24
CN104936589A (zh) 2015-09-23
AU2014210103B2 (en) 2018-09-06
CN112370427A (zh) 2021-02-19
PH12015501620A1 (en) 2015-09-28
MY192032A (en) 2022-07-24
US20170000764A1 (en) 2017-01-05
CL2015001649A1 (es) 2015-10-23
IL239657A0 (en) 2015-08-31
SG11201504499VA (en) 2015-08-28
US9427427B2 (en) 2016-08-30
BR112015015758B1 (pt) 2022-01-04
EA201591276A1 (ru) 2016-01-29
JP2016505029A (ja) 2016-02-18
BR112015015758B8 (pt) 2021-10-13
AR094548A1 (es) 2015-08-12

Similar Documents

Publication Publication Date Title
UA116004C2 (uk) Фармацевтична композиція з покращеною біодоступністю
IL266611A (en) Converted N-(3-fluorophenyl)-pyrrolidine substances, process for their preparation and medical use thereof
WO2015051030A3 (en) Stabilized polypeptides and uses thereof
WO2016149401A3 (en) Piperazine carbamates and methods of making and using same
CL2015001358A1 (es) Potenciadores del cftr deuterados
EP3324926A4 (en) COMPOSITION FOR CLEANING A KERATIN MATERIAL CONTAINING AMINO ACID SURFACTANT
WO2012168431A3 (en) Polypeptides
EP4309735A3 (en) Pharmaceutical composition of s-ketamine hydrochloride
AU2018256493A1 (en) Peptide Compositions
BR112017009405A2 (pt) composições antibióticas.
WO2015013330A3 (en) Ophthalmic uses of toxin-based therapeutic peptides and pharmaceutical compositions thereof
WO2015177175A3 (en) Novel specific-binding polypeptides and uses thereof
EA201491613A1 (ru) Катионные полимеры на основе гликогена
WO2015171558A3 (en) BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
IN2014MN02236A (uk)
WO2016014342A3 (en) Ang-(1-7) derviative oligopeptides and methods for using and producing the same
EP3133073A3 (en) Inhibitors of iap
CL2014001959A1 (es) Compuestos derivados de fenil-1h-imidazo[1,2-b]pirazol sustituidos; procedimiento de preparacion; composicion farmaceutica; y el uso en el tratamiento del cancer.
EP3302468A4 (en) SMALL MOLECULE ANALOGUES OF THE NEMO BINDING PEPTIDE
BR112015013675A2 (pt) composições compreendendo vortioxetina e donepezil
EA201491517A1 (ru) N-этил-n-фенил-1,2-дигидро-4,5-дигидрокси-1-метил-2-оксо-3-хинолинкарбоксамид, его получение и применения
EP4331622A3 (en) Integrin binding peptides and uses thereof
DK3259255T3 (da) (2r,4r)-5-(5'-chlor-2'-fluorbiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazol-2-carbonyl)amino]pentansyre
MX346113B (es) Polimorfos de n-(2-metoxibenzoil)-4-[(metilaminocarbonil)amino]ben cenosulfonamida.
EP3311817A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF EYES DISEASES WITH IMATINIB AS AN ACTIVE SUBSTANCE